JP2014524445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524445A5 JP2014524445A5 JP2014526241A JP2014526241A JP2014524445A5 JP 2014524445 A5 JP2014524445 A5 JP 2014524445A5 JP 2014526241 A JP2014526241 A JP 2014526241A JP 2014526241 A JP2014526241 A JP 2014526241A JP 2014524445 A5 JP2014524445 A5 JP 2014524445A5
- Authority
- JP
- Japan
- Prior art keywords
- muc1
- yeast
- composition
- immunotherapy
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 29
- 102100034256 Mucin-1 Human genes 0.000 claims 29
- 238000009169 immunotherapy Methods 0.000 claims 28
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 13
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 13
- 108020001507 fusion proteins Proteins 0.000 claims 7
- 102000037865 fusion proteins Human genes 0.000 claims 7
- 239000000556 agonist Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 230000001024 immunotherapeutic effect Effects 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161524407P | 2011-08-17 | 2011-08-17 | |
| US61/524,407 | 2011-08-17 | ||
| PCT/US2012/051299 WO2013025972A1 (en) | 2011-08-17 | 2012-08-17 | Yeast-muc1 immunotherapeutic compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017067243A Division JP6306238B2 (ja) | 2011-08-17 | 2017-03-30 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524445A JP2014524445A (ja) | 2014-09-22 |
| JP2014524445A5 true JP2014524445A5 (enExample) | 2015-10-01 |
| JP6122007B2 JP6122007B2 (ja) | 2017-04-26 |
Family
ID=47715495
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014526241A Active JP6122007B2 (ja) | 2011-08-17 | 2012-08-17 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
| JP2017067243A Active JP6306238B2 (ja) | 2011-08-17 | 2017-03-30 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
| JP2018040308A Active JP6571822B2 (ja) | 2011-08-17 | 2018-03-07 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
| JP2019145946A Pending JP2019194261A (ja) | 2011-08-17 | 2019-08-08 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017067243A Active JP6306238B2 (ja) | 2011-08-17 | 2017-03-30 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
| JP2018040308A Active JP6571822B2 (ja) | 2011-08-17 | 2018-03-07 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
| JP2019145946A Pending JP2019194261A (ja) | 2011-08-17 | 2019-08-08 | 酵母−ｍｕｃ１免疫療法用組成物およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9533031B2 (enExample) |
| EP (1) | EP2744918A4 (enExample) |
| JP (4) | JP6122007B2 (enExample) |
| KR (1) | KR102049928B1 (enExample) |
| CN (3) | CN109010809A (enExample) |
| AU (3) | AU2012296425B2 (enExample) |
| BR (1) | BR112014003477B1 (enExample) |
| CA (1) | CA2844500C (enExample) |
| IL (2) | IL230863B (enExample) |
| MX (1) | MX352892B (enExample) |
| RU (2) | RU2017143985A (enExample) |
| SG (1) | SG10201607663YA (enExample) |
| WO (1) | WO2013025972A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2170384T3 (en) | 2007-07-02 | 2016-07-25 | Etubics Corp | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| AP2013007110A0 (en) | 2011-02-12 | 2013-09-30 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis B infection |
| AU2012228937B2 (en) | 2011-03-17 | 2016-11-03 | Globeimmune, Inc. | Yeast-Brachyury immunotherapeutic compositions |
| BR112013032381B1 (pt) | 2011-06-14 | 2021-01-12 | Globeimmune, Inc. | composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta |
| RU2017143985A (ru) * | 2011-08-17 | 2019-02-14 | Глоубиммьюн, Инк. | Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения |
| US10138271B2 (en) | 2012-01-03 | 2018-11-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Native and agonist CTL epitopes of the MUC1 tumor antigen |
| EP2864792A1 (en) | 2012-06-26 | 2015-04-29 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| WO2014186047A1 (en) | 2013-03-19 | 2014-11-20 | Globeimmune, Inc. | Yeast-based immunotherapy for chordoma |
| WO2014160747A2 (en) | 2013-03-26 | 2014-10-02 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| TWI654200B (zh) | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
| CA3205348A1 (en) | 2013-10-23 | 2015-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use |
| KR102409372B1 (ko) | 2014-04-11 | 2022-06-16 | 글로브이뮨 | 효모 면역 요법 및 타입 i 인터페론 감도 |
| EP3236995A4 (en) | 2014-12-23 | 2018-07-18 | University of Maryland, Baltimore | Muc1 decoy peptides for treatment and prevention of bacterial infections |
| JP6647315B2 (ja) * | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
| EP3256140B1 (en) | 2015-01-09 | 2020-04-01 | Etubics Corporation | Compositions for ebola virus vaccination |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| IL303543A (en) | 2015-02-18 | 2023-08-01 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| EP3286213B1 (en) | 2015-04-20 | 2021-08-04 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| CN113106053A (zh) | 2015-04-21 | 2021-07-13 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
| WO2017023840A1 (en) * | 2015-08-03 | 2017-02-09 | Globeimmune, Inc. | Modified yeast-brachyury immunotherapeutic compositions |
| WO2017096247A1 (en) * | 2015-12-04 | 2017-06-08 | Mayo Foundation For Medical Education And Research | Methods and vaccines for inducing immune responses to multiple different mhc molecules |
| EP3400009A2 (en) | 2016-01-05 | 2018-11-14 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
| SG11201805621SA (en) | 2016-01-19 | 2018-08-30 | Pfizer | Cancer vaccines |
| WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
| EP3416661A4 (en) | 2016-02-18 | 2020-03-04 | Enlivex Therapeutics Ltd. | COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER |
| WO2017222619A2 (en) | 2016-03-24 | 2017-12-28 | Nantcell, Inc. | Sequence arrangements and sequences for neoepitope presentation |
| WO2018200389A1 (en) | 2017-04-24 | 2018-11-01 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
| CN119818663A (zh) | 2018-05-15 | 2025-04-15 | 全球免疫公司 | 用于诱导细胞免疫应答的重组酵母裂解物 |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| EP4135753A4 (en) | 2020-04-17 | 2024-05-01 | The Trustees of Columbia University in the City of New York | METHODS, COMPOSITIONS AND THEIR USES FOR REVERSING SARCOPENIA |
| CN113214210B (zh) | 2021-05-10 | 2022-03-04 | 合肥立方制药股份有限公司 | 一种二氢槲皮素的制备方法 |
| CN113185485B (zh) | 2021-05-10 | 2022-03-04 | 合肥立方制药股份有限公司 | 一种二氢槲皮素的半合成方法 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
| US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
| IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| AU727308B2 (en) | 1997-02-24 | 2000-12-07 | Dana-Farber Cancer Institute | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| DE19758400A1 (de) | 1997-12-30 | 1999-07-01 | Max Delbrueck Centrum | Tumorvakzine für MUC1-positive Karzinome |
| EP1137792B9 (en) | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| DE19906615A1 (de) * | 1999-02-17 | 2000-09-28 | Hanisch Franz Georg | Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung |
| JP2003510094A (ja) * | 1999-09-08 | 2003-03-18 | トランジェーヌ、ソシエテ、アノニム | Ｍｕｃ−１由来のペプチド |
| DE10006753A1 (de) | 2000-02-15 | 2001-08-16 | Zeiss Carl | Dreh-Schwenkeinrichtung für den Tastkopf eines Koordinatenmeßgerätes |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| ES2260078T3 (es) | 2000-04-06 | 2006-11-01 | Seer Pharmaceuticals, Llc. | Sistema de administracion microbiana. |
| US7083787B2 (en) | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
| US20060147477A1 (en) * | 2002-06-11 | 2006-07-06 | Glaxo Group Limited | Immunogenic compositions |
| AU2003251531A1 (en) * | 2002-06-14 | 2003-12-31 | Diadexus, Inc. | Compositions and methods relating to breast specific genes and proteins |
| US7439042B2 (en) * | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| AU2003301021C1 (en) | 2002-12-16 | 2010-02-18 | Globelmmune, Inc. | Yeast-based vaccines as immunotherapy |
| US7696306B2 (en) | 2003-07-11 | 2010-04-13 | Board of Agents of the University of Nebraska | Compositions and methods for preventing or treating cancer |
| GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| JP5285855B2 (ja) * | 2003-11-12 | 2013-09-11 | アメリカ合衆国 | 膵癌を処置および予防するためのカスタムベクター |
| JP2007535304A (ja) * | 2003-11-24 | 2007-12-06 | シドニー キンメル キャンサー センター | ムチン抗原ワクチン |
| US8828957B2 (en) * | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
| JP2008504219A (ja) * | 2003-12-11 | 2008-02-14 | シドニー キンメル キャンサー センター | 抗原に対する免疫を生じさせる方法 |
| ES2616337T3 (es) | 2003-12-12 | 2017-06-12 | Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors | Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1 |
| US20100034840A1 (en) * | 2005-07-11 | 2010-02-11 | David Apelian | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| JP2009544760A (ja) * | 2006-01-23 | 2009-12-17 | レコファーマ アーベー | 酵母におけるオリゴマンノースまたはヒト様グリカンを担持するタンパク質の産生およびその使用 |
| MX2008009929A (es) | 2006-02-02 | 2008-10-01 | Globeimmune Inc | Vacuna a base de levadura para inducir una respuesta inmune. |
| CN101448848B (zh) | 2006-03-27 | 2013-12-04 | 全球免疫股份有限公司 | Ras突变及其相关组合物和方法 |
| JP5570819B2 (ja) | 2007-02-02 | 2014-08-13 | グローブイミューン，インコーポレイテッド | 酵母を含む組成物および酵母を増殖させる方法 |
| EP2134358A1 (en) | 2007-03-19 | 2009-12-23 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| EP3375868A1 (en) | 2007-11-08 | 2018-09-19 | Dana Farber Cancer Institute, Inc. | Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28 |
| US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
| US8524669B2 (en) * | 2008-10-17 | 2013-09-03 | Dana-Farber Cancer Institute, Inc. | MUC-1 cytoplasmic domain peptides as inhibitors of cancer |
| WO2010065626A1 (en) * | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| EP2419126B1 (en) * | 2009-04-17 | 2018-01-10 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
| JP5913103B2 (ja) | 2009-09-14 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 |
| JP2013522302A (ja) | 2010-03-14 | 2013-06-13 | グローブイミューン，インコーポレイテッド | 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療 |
| WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| AP2013007110A0 (en) | 2011-02-12 | 2013-09-30 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis B infection |
| AU2012228937B2 (en) | 2011-03-17 | 2016-11-03 | Globeimmune, Inc. | Yeast-Brachyury immunotherapeutic compositions |
| BR112013032381B1 (pt) | 2011-06-14 | 2021-01-12 | Globeimmune, Inc. | composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta |
| RU2017143985A (ru) * | 2011-08-17 | 2019-02-14 | Глоубиммьюн, Инк. | Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения |
-
2012
- 2012-08-17 RU RU2017143985A patent/RU2017143985A/ru not_active Application Discontinuation
- 2012-08-17 AU AU2012296425A patent/AU2012296425B2/en active Active
- 2012-08-17 KR KR1020147006872A patent/KR102049928B1/ko active Active
- 2012-08-17 CN CN201810735110.0A patent/CN109010809A/zh active Pending
- 2012-08-17 WO PCT/US2012/051299 patent/WO2013025972A1/en not_active Ceased
- 2012-08-17 CN CN201280051154.2A patent/CN104024429B/zh active Active
- 2012-08-17 JP JP2014526241A patent/JP6122007B2/ja active Active
- 2012-08-17 RU RU2014109741A patent/RU2642300C2/ru active
- 2012-08-17 MX MX2014001717A patent/MX352892B/es active IP Right Grant
- 2012-08-17 EP EP12824638.6A patent/EP2744918A4/en active Pending
- 2012-08-17 CA CA2844500A patent/CA2844500C/en active Active
- 2012-08-17 CN CN202210208007.7A patent/CN114617958B/zh active Active
- 2012-08-17 SG SG10201607663YA patent/SG10201607663YA/en unknown
- 2012-08-17 BR BR112014003477-0A patent/BR112014003477B1/pt active IP Right Grant
-
2013
- 2013-03-14 US US13/803,757 patent/US9533031B2/en active Active
-
2014
- 2014-02-06 IL IL230863A patent/IL230863B/en active IP Right Grant
-
2016
- 2016-11-22 US US15/358,797 patent/US10188714B2/en active Active
-
2017
- 2017-03-30 JP JP2017067243A patent/JP6306238B2/ja active Active
- 2017-10-18 AU AU2017248462A patent/AU2017248462B2/en active Active
-
2018
- 2018-02-14 IL IL257533A patent/IL257533B/en active IP Right Grant
- 2018-03-07 JP JP2018040308A patent/JP6571822B2/ja active Active
- 2018-12-06 US US16/211,492 patent/US11065318B2/en active Active
-
2019
- 2019-08-08 JP JP2019145946A patent/JP2019194261A/ja active Pending
-
2020
- 2020-01-08 AU AU2020200137A patent/AU2020200137B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524445A5 (enExample) | ||
| ZA202308846B (en) | Cx3cr1-binding polypeptides | |
| JP2011155981A5 (enExample) | ||
| HK1216894A1 (zh) | 多價結合蛋白組合物 | |
| MX2014005546A (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
| CL2012002095A1 (es) | Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa | |
| NZ616761A (en) | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same | |
| WO2015051199A3 (en) | Modified pseudomonas exotoxin a | |
| GB201206559D0 (en) | Polypeptide | |
| NZ761188A (en) | Antibody molecules to tim-3 and uses thereof | |
| JP2016185981A5 (enExample) | ||
| MY176331A (en) | Carbohydrate degrading polypeptide and uses thereof | |
| WO2014144632A8 (en) | Human pac1 antibodies | |
| WO2013040093A3 (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
| MX380772B (es) | 3-epimerasa. | |
| HK1200468A1 (en) | Anti-erbb3 antibodies and uses thereof | |
| JP2012126742A5 (enExample) | ||
| IN2014DN00202A (enExample) | ||
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| SI3191511T1 (en) | Improved TNF binders | |
| JP2014525439A5 (enExample) | ||
| WO2015160928A3 (en) | Isolated t cell receptors and methods of use therefor | |
| PH12015500771A1 (en) | Novel fc gamma receptor iib variants | |
| MX374403B (es) | Secuencia de endolisina kz144 modificada. | |
| WO2014202208A8 (fr) | Polypeptide ayant la capacite de former des branchements d'unites glucosyle en alpha-1,3 sur un accepteur |